What is the MRUS share price today?

This page shows the latest available Merus N.V. (MRUS) price with its change against the prior close. Values are delayed or previous-close, not real-time.

Where is Merus N.V. listed?

Merus N.V. trades on Nasdaq under the symbol MRUS, ISIN NL0011606264.

How large is Merus N.V.?

Its market capitalisation is approximately 6.83B USD, based on the latest available price and share count from our data provider.

Nasdaq · MRUS · ISIN NL0011606264

Merus N.V.

No trading activity has been reported for this listing since January 2, 2026. It may be delisted, halted or inactive.

90.00 USD

January 2, 2026

Merus N.V. (MRUS) trades on Nasdaq and operates in the Biotechnology industry. Its market capitalisation is approximately 6.83B USD. The company reports around 260 employees. Its ISIN is NL0011606264. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Key facts

Exchange

Nasdaq

ISIN

NL0011606264

Sector

Healthcare

Industry

Biotechnology

Country

Market cap

6.83B USD

Employees

260

Previous close

90.00 USD

Day range

90.00 – 90.00

52-week range

33.19 – 97.14

Volume

2.72M

50-day average

95.61 USD

200-day average

68.01 USD

Asset type

Equity

About Merus N.V.

Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoing Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, and is also in Phase 1/2 clinical trials for solid tumors that exhibit Neuregulin 1 expression. Merus is also actively developing several other compounds: MCLA-158: In Phase 1 clinical trials for solid tumors. MCLA-145: Also in Phase 1 clinical trials for various solid tumors. MCLA-129: Progressing through Phase 1/2 clinical trials for advanced non-small cell lung cancer (NSCLC) and other solid tumors. ONO-4685: Currently in Phase 1 clinical trials to address relapsed/refractory T-cell lymphoma. Furthermore, Merus engages in strategic partnerships. It collaborates with Betta Pharmaceuticals Co. Ltd on the research and development of specific bispecific antibody candidates, including MCLA-129. Additionally, Incyte Corporation is partnering with Merus for the development of MCLA-145.

Company website

Frequently asked

What is the MRUS share price today?: This page shows the latest available Merus N.V. (MRUS) price with its change against the prior close. Values are delayed or previous-close, not real-time.
Where is Merus N.V. listed?: Merus N.V. trades on Nasdaq under the symbol MRUS, ISIN NL0011606264.
How large is Merus N.V.?: Its market capitalisation is approximately 6.83B USD, based on the latest available price and share count from our data provider.

All Merus N.V. data comes from exchange and provider feeds for Nasdaq and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.